# Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma

> **NCT03546166** · PHASE2 · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nice** · enrollment: 24 (actual)

## Conditions studied

- Carcinoma

## Interventions

- **DRUG:** Picato 0.05% Topical Gel

## Key facts

- **NCT ID:** NCT03546166
- **Lead sponsor:** Centre Hospitalier Universitaire de Nice
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-26
- **Primary completion:** 2021-03-11
- **Final completion:** 2022-03-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03546166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03546166, "Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03546166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*